Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: a perspective from COMBACTE’s STAT-Net

PURPOSE: In this era of rising antimicrobial resistance, slowly refilling antibiotic development pipelines, and an aging population, we need to ensure that randomized clinical trials (RCTs) determine the added benefit of new antibiotic agents effectively and in a valid way, especially for severely i...

Descripción completa

Detalles Bibliográficos
Autores principales: Timsit, Jean-François, de Kraker, Marlieke E. A., Sommer, Harriet, Weiss, Emmanuel, Bettiol, Esther, Wolkewitz, Martin, Nikolakopoulos, Stavros, Wilson, David, Harbarth, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5487537/
https://www.ncbi.nlm.nih.gov/pubmed/28466147
http://dx.doi.org/10.1007/s00134-017-4802-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5487537/
https://www.ncbi.nlm.nih.gov/pubmed/28466147
http://dx.doi.org/10.1007/s00134-017-4802-4

Ejemplares similares